Insider Selling: Disc Medicine (NASDAQ:IRON) Insider Sells $63,825.00 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) insider Rahul Khara sold 851 shares of the firm’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $75.00, for a total value of $63,825.00. Following the completion of the transaction, the insider owned 52,173 shares of the company’s stock, valued at approximately $3,912,975. This represents a 1.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Rahul Khara also recently made the following trade(s):

• On Monday, June 29th, Rahul Khara sold 1,649 shares of Disc Medicine stock. The shares were sold at an average price of $75.00, for a total value of $123,675.00.
• On Thursday, June 18th, Rahul Khara sold 7,500 shares of Disc Medicine stock. The shares were sold at an average price of $70.22, for a total value of $526,650.00.

Disc Medicine Price Performance

Shares of Disc Medicine stock traded down $1.36 on Tuesday, reaching $73.14. The stock had a trading volume of 729,507 shares, compared to its average volume of 612,517. The business’s 50 day moving average is $68.99 and its two-hundred day moving average is $70.77. The company has a current ratio of 24.00, a quick ratio of 24.00 and a debt-to-equity ratio of 0.04. Disc Medicine, Inc. has a 1 year low of $40.00 and a 1 year high of $99.50. The company has a market cap of $2.79 billion, a P/E ratio of -11.05 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). As a group, research analysts anticipate that Disc Medicine, Inc. will post -6.74 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on IRON shares. Wall Street Zen upgraded Disc Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a research note on Monday, April 20th. Morgan Stanley raised their price target on Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a report on Monday, June 15th. Wells Fargo & Company lifted their price target on Disc Medicine from $78.00 to $79.00 and gave the company an “overweight” rating in a research report on Monday, March 2nd. Finally, Wedbush reaffirmed an “outperform” rating and issued a $88.00 target price on shares of Disc Medicine in a research note on Wednesday, June 10th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $105.80.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IRON. JPMorgan Chase & Co. increased its stake in Disc Medicine by 110.0% in the fourth quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock valued at $125,557,000 after acquiring an additional 828,248 shares during the last quarter. BVF Inc. IL bought a new stake in Disc Medicine during the fourth quarter worth about $51,616,000. Jennison Associates LLC purchased a new position in shares of Disc Medicine in the 4th quarter worth about $42,252,000. Perceptive Advisors LLC purchased a new position in shares of Disc Medicine in the 4th quarter worth about $35,794,000. Finally, RA Capital Management L.P. increased its position in shares of Disc Medicine by 25.3% during the 4th quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock valued at $156,925,000 after purchasing an additional 399,026 shares during the last quarter. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.